LY2109761
Product Specifications
UNSPSC Description
LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.
Target Antigen
Autophagy; TGF-β Receptor
Type
Reference compound
Related Pathways
Autophagy;TGF-beta/Smad
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY2109761.html
Purity
99.64
Solubility
DMSO : 6.67 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
N12N=C(C(C3=C4C=CC(OCCN5CCOCC5)=CC4=NC=C3)=C1CCC2)C6=NC=CC=C6
Molecular Weight
441.52
References & Citations
[1]Melisi D, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther, 2008, 7(4), 829-840.|[2]Fransvea E, et al. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 47(5), 1557-1566.|[3]Zhang M, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res, 2011, 71(23), 7155-7167.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-12075/LY2109761-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-12075/LY2109761-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
700874-71-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
